Bloom X³ — life sciences venture studio
Multiple global medicines, delivered to patients.
Integrating global hands-on experience to build and implement a next-generation drug-creation system.
An integrated life sciences venture cube — across discovery science, drug development, and capital. Global operations — a global network hub.
Contact us Read the Founder Philosophy →
Founder
Hiro Kimura ／ Ph.D., R.Ph.
Track record
Following his graduate degree at the University of Tokyo, he conducted research at a top laboratory at St. Jude Children’s Research Hospital. His long-standing Drug Discovery / translational research collaboration with Genentech and Curis was launched in 2012 and became a global blockbuster. He went on to lead global oncology research programs within R&D at Takeda Pharmaceutical. At Astellas, he led the R&D and business divisions, contributing to the launch of multiple approved medicines through M&A integration. Further, as CVC site head in San Francisco, he led strategic investments and drove multiple special partnerships with top U.S. and European VCs, serving as a Board member and on Advisory boards — the division’s results ranked 7th worldwide.
Academic & training: St. Jude Children’s Research Hospital, University of Tokyo (International Graduate Program in Life Sciences), Kyoto University Graduate School of Medicine.
Visiting researcher: National Center for Geriatrics and Gerontology.
Advisory: additional academia advisory roles.
AdvisorsAn advisor team of global standing — supporting Bloom X³ across the U.S. and Japan.
Meet the team →Advisory Board ― World-class minds on board
Tom Curran, Ph.D., FRS
Royal Society Fellow
A world authority in cancer biology. Held executive roles at multiple U.S. institutions. Served as President of the AACR; elected Fellow of the Royal Society and member of the U.S. National Academy of Medicine.
Profile →
Joe Bolen, Ph.D.
Drug Discovery Leader
A drug-discovery & business professional. President of R&D at Moderna; led oncology research at Takeda and Millennium. Discoverer of tyrosine-kinase oncogenes.
Profile →
Guanghui Hu, Ph.D.
Serial Entrepreneur
EY Entrepreneur of the Year; a serial entrepreneur who has founded biotech VCs and incubators.
Profile →
Karuppiah Kannan, Ph.D.
Oncology Drug Discovery
A veteran of oncology drug discovery behind four FDA-approved medicines (Ninlaro, Adcetris and more), from IND to the clinic.
Profile →What we do
NewXus Fund
At a global pharmaceutical company, our founder built hands-on R&D, BD, and CVC experience at scale. NewXus Fund is an early-stage life sciences fund grounded in that experience — delivering global-standard due diligence and dedicated, supportive engagement to every founder we back.
Investment scope
Refractory cancer · Regeneration & ageing · Next-gen platforms
Geography
Japan · U.S. · Europe
Details →Yncubator
Hands-on incubation that grounds next-generation science to global standards. We architect the foundations — IP strategy, R&D design, commercialization path — that founders cannot shortcut.
Lead initiative
Project 1102 (BNCT) — multi-layer academic collaboration partnerships · government-backed initiative.
Collaborative project
Silicon Valley startups
Details →Zero1
A platform that surfaces — and creates — the foundational value of life sciences innovation. Built on advanced technologies and global-network collaboration, engineered to deliver value across research, industry, and capital.
Partnering with a U.S. ally on a drug-discovery ecosystem — an AI-driven, integrated Ecosystem Platform, VentriLink.
Focus
Academia · AI · Quantum · Cross-border Ecosystem
Details →Special Business Collaboration & Partnership Desk
Engaged after a direct discussion with the founder, within a limited slot — from short-term project consultation to long-term support
Track record
Multiple leading global consulting firms; building ventures spun out of academia
Where We Create Medicines
Where we create medicines.
The origin of drug creation — the fields we take on.
Three concepts, not literal circles — the origins of drug creation. At their overlap, the next-generation medicines Bloom X³ creates. Individual projects (BNCT/1102) sit in the Y card.
Partners & Collaborations
Research & Clinical
Academic
Government Support
Global Network
Tokyo · Boston · NY · NJ · Bay Area
© Bloom X³ Co., Ltd.